ANKRD26

Across TCGA pan-cancer cohorts, ANKRD26 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD26 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANKRD26 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD26 expression acts as an unfavorable survival marker.

PDAC, UCEC, and LSCC are the cancer types where ANKRD26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.229	0.497	.001	30	view →
UCEC	OS	Median	All	0.822	0.978	.018	4	view →
LSCC	OS	Median	III,IV	0.759	0.932	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANKRD26–PDAC (DFS)

Open the PDAC breakdown →